Poster note: MALDI high-throughput screening beyond 100,000 samples per day in drug discovery

17 November 2015  •  Author(s): Bruker and Novartis

Biochemical high-throughput screening (HTS) assays in the pharmaceutical drug development process are generally based on fluorescence detection methods, such as timeresolved fluorescence energy transfer and fluorescence intensity, which often require chemical derivatisation of one or more detection reagents.

Poster Note PN-05 MALDI High-Throughput Screening beyond 100,000 Samples per Day in Drug DiscoveryLabel-free methods based on mass spectrometry are rapidly expanding into HTS development. These MS-based methods include multiplexed LC-MS and SPE-MS techniques and have typical cycle times of between 6 and 30 seconds per sample. Using MALDI-TOF in HTS assays provides significant benefits over multiplexed LC-MS and SPE-MS techniques by dramatically increasing sample analysis speed. MALDI-TOF approaches can also significantly reduce costs and the amount of solvent/ chemical waste. This work focuses on the improvement of MALDI-TOF automation parameters to further increase sample analysis speed in HTS assays to more than 100,000 samples per day.

The rest of this content is restricted to logged-in subscribers. Login or register (it's free!) to view the full content.

Comments are closed.


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...